Predicting Survival and Recurrence in Lung Cancer
Author Information
Author(s): M Diezl, A Torres, ML Maestro, MD Ortega, A Gomez, M Pollan, JA Lopez, A Picardo, F Hernando, JL Balibreal
Primary Institution: San Carlos University Hospital, Madrid, Spain; Cancer Epidemiology Unit, National Centre of Epidemiology, Instituto de Salud 'Carlos III', Madrid, Spain.
Hypothesis
Can serum and cytosolic levels of CEA, CA125, and SCC antigens predict survival and recurrence in non-small-cell lung cancer patients?
Conclusion
CA125 and CEA levels provide additional prognostic information that complements TNM classification and histological type in assessing the risk of death or recurrence in lung cancer patients.
Supporting Evidence
- High CA125 levels in cytosol were associated with a significantly lower probability of survival.
- Patients with large cell carcinoma had a significantly lower probability of survival compared to those with squamous carcinoma and adenocarcinoma.
- The cumulative probability of survival over 36 months was 45%.
Takeaway
Doctors can use certain blood tests to better understand how likely it is that lung cancer will come back or be deadly after surgery.
Methodology
The study analyzed serum and cytosolic levels of CEA, CA125, and SCC in 108 patients who underwent surgery for lung cancer, assessing their relationship with survival and recurrence.
Limitations
The study did not include patients who received chemotherapy or radiation before surgery, which may limit the generalizability of the findings.
Participant Demographics
99 men and 9 women, mean age 61 years.
Statistical Information
P-Value
p<0.001 for CA125 in cytosol
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website